自体血清滴眼液治疗系统性自身免疫病患者眼表疾病的应用
回顾性干预性病例系列分析2009至2015年51例(101眼)系统性自身免疫病相关慢性眼表疾病患者使用20%-50%自体血清滴眼液的情况。首次与末次随访相比,角膜点状上皮糜烂、丝状角膜病变比例下降,完全客观改善占30%、部分改善占55%,主观症状完全改善占34.6%,随访期间未观察到不良反应。作者认为自体血清滴眼液是安全有效的辅助治疗。
要点
- 51例(101眼)系统性自身免疫病相关眼表疾病患者接受20%-50%自体血清滴眼液治疗,平均使用14.3±11.7个月。
- 角膜点状上皮糜烂比例由92.1%降至52.5%(P < .001),丝状角膜病变由22.8%降至9.9%(P = .02)。
- 主观症状完全改善占34.6%、部分改善占50.5%、无改善占14.9%,随访期间未观察到不良反应。
核心结论
- 自体血清滴眼液是改善系统性自身免疫病相关眼表疾病客观体征和主观症状的安全有效辅助治疗。
研究设计与样本
- 回顾性、干预性病例系列,分析2009年至2015年因慢性眼表疾病接受20%-50%自体血清滴眼液治疗的系统性自身免疫病患者记录。
- 共纳入51例患者(101眼),平均年龄59.8±13.2岁,女性占72.5%。
- 比较首次与末次随访时主观干眼症状、角膜客观干眼染色及裂隙灯所见(点状上皮糜烂、丝状角膜病变、角膜上皮缺损)。
- 尝试以1至4分量表标准化主观与客观结局:加重(1)、无改善(2)、部分改善(3)、完全缓解(4)。
主要发现
- 自体血清滴眼液平均使用14.3±11.7个月。
- 初始裂隙灯所见完全客观改善占30%的眼、部分改善占55%的眼。
- 点状上皮糜烂比例由92.1%降至52.5%(P < .001),丝状角膜病变由22.8%降至9.9%(P = .02),角膜上皮缺损由5%降至2%(P = .44)。
- 主观症状完全改善占34.6%的患者、部分改善占50.5%、无改善占14.9%。
- 随访期间未观察到不良反应。
临床怎么用
- 作者认为自体血清滴眼液是改善系统性自身免疫病相关眼表疾病客观体征与主观症状的安全有效辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe the safety and efficacy of autologous serum tears (AST) in managing ocular surface disease resistant to conventional therapy in patients with systemic autoimmune disease(s). DESIGN: Retrospective, interventional case series. METHODS: Records of patients from 2009 to 2015 with systemic autoimmune disease treated with AST (20%-50%) for chronic surface disease were analyzed. Standardized measures of subjective dry eye symptoms, objective dry eye staining of the cornea, and slit-lamp findings including punctate epithelial erosion (PEE), filamentary keratopathy (FK), and corneal epithelial defects (KED) were compared during first and last visit. We attempted to standardize outcomes by creating a scale from 1 to 4 for subjective and objective components: worsening (1), no improvement (2), partial improvement (3), and complete resolution (4). RESULTS: Fifty-one patients (101 eyes) were included. The mean age was 59.8 ± 13.2 years (72.5% female). Average use of AST was 14.3 ± 11.7 months. Complete objective improvement of initial slit-lamp findings was achieved in 30% and partial improvement in 55% of eyes. Presence of PEE, FK, and KED decreased from 92.1% to 52.5% (P < .001), from 22.8% to 9.9% (P = .02), and from 5% to 2% (P = .44) of the eyes, respectively. Full subjective improvement of symptoms was achieved in 34.6%, partial in 50.5%, and none in 14.9% of patients. No adverse side effects were noted during follow-up. CONCLUSIONS: AST are a safe and effective adjunct therapy in improving both objective signs and subjective symptoms of ocular surface disorders associated with systemic autoimmune disease(s).
引用
- Ali TK, Gibbons A, Cartes C, et al. Use of Autologous Serum Tears for the Treatment of Ocular Surface Disease From Patients With Systemic Autoimmune Diseases. Am J Ophthalmol. 2018. PMID: 29470971. doi:10.1016/j.ajo.2018.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。